Glucocorticoids are drugs widely used as anti-inflammatories and immunosuppressants. However, its use presents a number of limitations related to adverse effects and dosage forms for administration by different routes. In addition, commercial anti-inflammatories have serious adverse effects such as gastric ulcers.
The technology allows to obtain new compounds derived from glucocorticoids, with greater anti-inflammatory and analgesic activity than the original prototype compounds. The differential pharmacokinetic profile of the compounds allows them to be used as a slow release form of the glucocorticoid, thereby reducing the need for multiple administrations, facilitating the use and improving adherence to the therapy by the patient.
Agência Unesp de Inovação
Tel: +55 11 5627.0696